DI GIORGIO, Eros
 Distribuzione geografica
Continente #
NA - Nord America 1.797
EU - Europa 481
AS - Asia 227
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.509
Nazione #
US - Stati Uniti d'America 1.789
IT - Italia 189
UA - Ucraina 83
CN - Cina 73
DE - Germania 50
VN - Vietnam 37
IE - Irlanda 35
SE - Svezia 29
SG - Singapore 29
JP - Giappone 28
GB - Regno Unito 27
TR - Turchia 27
FI - Finlandia 25
HK - Hong Kong 18
CZ - Repubblica Ceca 13
BE - Belgio 12
CA - Canada 8
IN - India 7
NL - Olanda 5
AT - Austria 4
CH - Svizzera 4
CO - Colombia 3
IR - Iran 3
KR - Corea 3
ES - Italia 2
EU - Europa 1
FR - Francia 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
MY - Malesia 1
Totale 2.509
Città #
Woodbridge 222
Chandler 206
Fairfield 180
Ann Arbor 146
Houston 138
Ashburn 105
Seattle 88
Wilmington 86
Cambridge 69
Udine 60
Dearborn 49
Jacksonville 46
Dong Ket 37
Dublin 29
Singapore 28
Princeton 27
Beijing 24
Hong Kong 15
Kocaeli 14
Baltimore 13
Codroipo 13
Izmir 13
Falls Church 12
New York 12
Brno 11
Brussels 11
Des Moines 11
San Diego 11
Redmond 10
Birmingham 9
Nanjing 9
Philadelphia 9
Cincinnati 7
London 7
Osaka 7
Rockville 7
Milan 6
Vancouver 6
Wuhan 6
Aachen 5
Monmouth Junction 5
Norwalk 5
Ogden 5
Boardman 4
Bologna 4
Cagliari 4
Grafing 4
Indianapolis 4
Munich 4
Phoenix 4
Quzhou 4
Sheffield 4
Tokyo 4
Bucaramanga 3
Faenza 3
Hyderabad 3
Kunming 3
Kyoto 3
Liverpool 3
Markaz 3
Minatomirai 3
Plainville 3
Redwood City 3
Saffron Walden 3
San Donà di Piave 3
Scafati 3
Shenyang 3
Stuttgart 3
Vienna 3
Brooklyn 2
Busto Arsizio 2
Chennai 2
Colleferro 2
Cremona 2
Evanston 2
Ferrara 2
Gandhinagar 2
Grado 2
Guangzhou 2
Hefei 2
Heidelberg 2
Helsinki 2
Lappeenranta 2
Leiderdorp 2
Los Angeles 2
Ma On Shan 2
Mereto di Tomba 2
Messina 2
Minoh 2
Nishioizumi 2
Padova 2
Prague 2
Providence 2
Sacramento 2
San Jose 2
Shenzhen 2
Simi Valley 2
South San Francisco 2
Storrs 2
Susakicho 2
Totale 1.929
Nome #
Super-enhancer landscape rewiring in cancer: The epigenetic control at distal sites 212
The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness 174
The control operated by the cell cycle machinery on mef2 stability contributes to the downregulation of cdkn1a and entry into s phase 158
Regulation of class IIa HDAC activities: It is not only matter of subcellular localization 155
Transformation by different oncogenes relies on specific metabolic adaptations 138
MEF2 and the tumorigenic process, hic sunt leones 132
Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors 126
Beside the MEF2 axis: Unconventional functions of HDAC4. 117
Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors. 109
The MEF2-HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro 103
Selective class IIa HDAC inhibitors: myth or reality. 98
METABOLIC ALTERATION AND MITOCHONDRIAL BIOENERGETIC PROFILE IN HDAC4-DRIVEN TUMORIGENESIS 93
MEF2 is a converging hub for HDAC4 and PI3K/Akt-induced transformation. 90
HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells 81
Different class IIa HDACs repressive complexes regulate specific epigenetic responses related to cell survival in leiomyosarcoma cells 79
Quis custodiet ipsos custodes (Who controls the controllers)? two decades of studies on HDAC9 75
Unscheduled HDAC4 repressive activity in human fibroblasts triggers TP53-dependent senescence and favors cell transformation 73
GSK3β is a key regulator of the ROS-dependent necrotic death induced by the quinone DMNQ 70
Genetic programs driving oncogenic transformation: Lessons from in vitro models 68
THE REPRESSION OF MEF2 TRANSCRIPTION FACTORS EXERTED BY CLASS IIA HDACS AND THEIR DEGRADATION STIMULATED BY CDK4 DETERMINE THE ACQUISITION OF HALLMARKS OF TRANSFORMATION IN FIBROBLASTS. 67
The Histone Code of Senescence 56
Enhancing proteotoxic stress in leiomyosarcoma cells triggers mitochondrial dysfunctions, cell death, and antitumor activity in vivo 47
HDAC4 degradation during senescence unleashes an epigenetic program driven by AP-1/p300 at selected enhancers and super-enhancers 45
Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy 44
A regulative epigenetic circuit supervised by HDAC7 represses IGFBP6 and IGFBP7 expression to sustain mammary stemness 43
A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells 39
Photosensitization of pancreatic cancer cells by cationic alkyl-porphyrins in free form or engrafted into POPC liposomes: The relationship between delivery mode and mechanism of cell death 28
Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription 26
Inhibiting the coregulator CoREST impairs Foxp3+ Treg function and promotes antitumor immunity 24
Fetal growth at term and placental oxidative stress in a tissue micro-array model: a histological and immunohistochemistry study 23
Endogenous Retroviruses (ERVs): Does RLR (RIG-I-Like Receptors)-MAVS Pathway Directly Control Senescence and Aging as a Consequence of ERV De-Repression? 18
Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells 12
NRF2 interacts with distal enhancer and inhibits nitric oxide synthase 2 expression in KRAS-driven pancreatic cancer cells 7
Suppression of the KRAS-NRF2 axis shifts arginine into the phosphocreatine energy system in pancreatic cancer cells 6
Transcription of endogenous retroviruses in senescent cells contributes to the accumulation of double-stranded RNAs that trigger an anti-viral response that reinforces senescence 6
Changes in chromatin accessibility and transcriptional landscape induced by HDAC inhibitors in TP53 mutated patient-derived colon cancer organoids 6
Folding of Class IIa HDAC Derived Peptides into α-helices Upon Binding to Myocyte Enhancer Factor-2 in Complex with DNA 5
Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells 1
Totale 2.654
Categoria #
all - tutte 8.455
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.455


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020504 31 20 12 63 34 72 77 50 54 47 20 24
2020/2021446 20 31 14 44 32 32 23 30 68 57 28 67
2021/2022314 28 38 8 22 10 16 27 5 28 42 58 32
2022/2023447 36 46 10 63 38 89 3 30 46 8 31 47
2023/2024391 53 24 37 20 47 26 32 56 16 20 19 41
2024/202511 11 0 0 0 0 0 0 0 0 0 0 0
Totale 2.654